I read with great interest the article by Hafkamp et al.
Makay
Balahan
B
D019440:Anti-Obesity Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001663:Bilirubin / Q000378:metabolism; D003414:Crigler-Najjar Syndrome / Q000188:drug therapy* / Q000378:metabolism; D003967:Diarrhea / Q000139:chemically induced / Q000378:metabolism; D004764:Enterohepatic Circulation; D005243:Feces / Q000737:chemistry; D006801:Humans; D007783:Lactones / Q000009:adverse effects / Q000627:therapeutic use*; D050356:Lipid Metabolism / Q000187:drug effects; D000077403:Orlistat; D016896:Treatment Outcome
D019440:Anti-Obesity Agents; D007783:Lactones; D000077403:Orlistat; D001663:Bilirubin